Please Wait...

Bioclinica Medical Imaging & Biomarkers Announces Pivotal Hires

Kraus, Zaim, Levy assume key roles in steering the global trials leader

January 18, 2017

Bioclinica®, a provider of specialized science and technology-enabled services supporting clinical trials, today announced three executive additions to its global Medical Imaging & Biomarkers leadership team. With global headquarters in Princeton, New Jersey, Bioclinica’s Medical Imaging & Biomarkers business segment is the world clinical trial leader in medical imaging, providing cardiac safety monitoring services, specialized biochemical marker analysis, and clinical lab services in the Bioclinica molecular marker laboratory. Joining Bioclinica are Andrew Kraus, Chief Operating Officer; Souhil Zaim, MD, Head of Global Medical and Science Affairs; and Sara Levy, Vice President, Client Services. All three will report to David Herron, President, Medical Imaging & Biomarkers.

As the global leader in medical imaging and biomarkers, our teams are proud to have supported more than 3,000 clinical trials and 149 FDA approvals. An incomparable clinical trial track record spanning three decades attracts the world’s best in our domain. I am very happy to have these three, multi-talented individuals join our incredible team, adding their expertise, experience and passion for creating value for patients, customers and the industry.

- David Herron, President Medical Imaging & Biomarkers

Kraus is a recognized clinical research industry senior executive with more than 24 years of technical and regulatory knowledge, and a track record of financial growth and operational delivery. Among his primary responsibilities Kraus will be pivotal in driving strategic planning, spearheading technology-enabled global operations, supporting Bioclinica’s tremendous growth, and driving superior outcomes for clients. Most recently, Kraus was chief operating officer and treasurer of the Cardiovascular Research Foundation in New York City where he led a period of historical growth. Prior to this he was with ICON, plc. for ten years serving as executive vice president, Global Data Technologies after a tenure as executive vice president and chief technology officer of the Medical Imaging Division. Kraus has co-founded two successful businesses in the clinical trials services industry after beginning his long career at Bio-Imaging Technologies, which would later become Bioclinica. Kraus has both a bachelor’s and a master’s degree in Bioengineering from the University of Pennsylvania.

Dr. Zaim is a recognized medical imaging industry senior executive with more than 25 years of medical, scientific and industry experience and was most recently chief medical officer at Median Technologies. He will be responsible for ensuring the strategic and long-term medical, scientific and technical development of Bioclinica’s Medical and Science Affairs organization in concert with the Medical Imaging & Biomarkers’ Chief Medical Officer, Dr. Michael O’Neal, and Chief Science Officer, Dr. Thomas Fuerst. Dr. Zaim was previously with SYNARC (merged with Bioclinica in March 2014) for more than a decade in various leadership roles, including medical director, chief medical officer, vice president of radiology, and director of radiology services, Europe. In these roles, Dr. Zaim established and developed global medical and science affairs teams supporting an array of clinical trial indications. Dr. Zaim is regularly published in peer-reviewed journals, and has extensive central reading and adjudication experience encompassing thousands of patients in hundreds of clinical trials in Oncology, Arthritis, Osteoporosis and other areas. Prior to this he was assistant professor of Radiology at the University of California at San Francisco. He earned a medical degree from the University of Algiers and is board certified in Radiology with a certificate in Magnetic Resonance, both from the University of Paris. Dr. Zaim is a member of the Radiological Society of North America, the European Society of Radiology, Osteoarthritis Research Society International, and the American Society of Clinical Oncology.

Levy is a proven clinical research operating executive with more than 18 years of client and clinical data management experience. She was most recently clinical practice director at Penobscot Community Health Center leading a health service delivery venture with athenahealth. She will provide executive leadership for Bioclinica’s clinical project management teams across the Medical Imaging & Biomarker business, supporting operations and delivery focused on consistency of service and customer satisfaction, and will play a pivotal role in the ongoing development of new client-service offerings. Levy is a graduate of Trinity College with a Bachelor of Science degree in Psychology and Cognitive Science with a focus on the neurosciences.

About Bioclinica
Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: